Contact: Ralph Barry, Chief Business Officer, Aegis Therapeutics LLC
1-858-618-1400 Ext. 102, Email: rbarry@aegisthera.com

Aegis Awarded Patent for Intranasal Administration of Active Agents to the Central Nervous System

SAN DIEGO, CA Nov. 11, 2014/MarketWire– Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,883,728, providing for highly efficient delivery of drugs to the central nervous system via simple metered nasal spray formulations.

For more than 30 years, considerable efforts have been made to enhance the safe delivery of therapeutic molecules across the blood brain barrier (BBB) of the Central Nervous System (CNS) which restricts the entry of most pharmaceuticals into the brain. The development of new drugs for treatment of CNS disorders has been hindered because most drugs are unable to cross the BBB. Aegis excipient technology permits highly efficient delivery of drugs to the brain and central nervous system, using simple aqueous formulations administered by commercially available metered spray devices.

The drug delivery claims broadly cover all small molecule as well as peptide and protein drugs to the CNS. As a result, potential CNS applications include neurodegenerative conditions such as Parkinson’s disease, ALS (amyotrophic lateral sclerosis), multiple sclerosis, seizures, tumors, vascular conditions, cluster headaches, trigeminal neuralgia, autoimmune conditions, and infections, among others. Aegis licenses its Intravail-based drug delivery technology to pharmaceutical companies developing drugs for treatment applications in a broad spectrum of diseases in the CNS and non CNS disease areas.

About Aegis Therapeutics 

Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive systemic delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability. Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding the oxidative damage caused by polysorbate surfactants currently found in most protein injectable drugs.

For more information about Aegis, please visit: http://aegisthera.com/.